IMPACT Therapeutics firma un acuerdo de licencia exclusiva con Pharmanovia

PartnershipsenaparibPositive

AI Analysis

Summary

IMPACT Therapeutics has signed an exclusive licensing agreement with Pharmanovia for senaparib in Europe, Middle East, North Africa, Australia and New Zealand, expanding the drug's commercial reach in these regions.

Outcome Details

Exclusive license agreement for senaparib in Europe, Middle East, North Africa, Australia and New Zealand

Importance:7/10

Sentiment:

0.60

licensingpartnershipsenaparibgeographic expansion

Related Companies

$07630.HK

Read the original article

Published by PR Newswire Pharma on August 3, 2026 6:01 AM

Read Original